VRDN (Viridian Therapeutics) Q4/FY2025 Earnings & REVEAL-1 Phase 3 Topline

Price: $27.39 (as of market open March 30, down ~3% premarket) Market Cap: ~$3.5B Stage: Late clinical / Pre-commercial (BLA stage) Focus: Thyroid eye disease (TED). Two-asset portfolio targeting IGF-1R. Elegrobart (subcutaneous) and veligrotug (IV)

The Numbers

• Revenue: Zero. Pre-revenue, BLA stage

• R&D FY2025: $176.1M (not broken out in the PR but referenced in prior filings)

• Cash (Dec 31, 2025): $875M

• Runway: Company says cash plus near-term royalty milestones plus anticipated commercial revenues from veligrotug and elegrobart (if approved) fund through profitability. That's a bold claim but $875M is a war chest

$875M in cash is a fortress balance sheet for a clinical-stage biotech. No financing risk here. They can self-fund two product launches.

REVEAL-1 Phase 3 Results (elegrobart, active TED)

132 patients, randomized 1:1:1 across Q4W, Q8W, and placebo.

The wins:

• Primary endpoint hit with high statistical significance. Q4W proptosis responder rate 54% vs 18% placebo (p < 0.0001)

• Q8W proptosis responder rate even better at 63% vs 18% placebo (p < 0.0001)

• Proptosis mean change Q4W: -2.33mm vs -0.81mm placebo (p < 0.0001)

• Proptosis mean change Q8W: -2.50mm vs -0.81mm placebo (p < 0.0001)

• Diplopia responder rate Q4W: 71% vs 32% placebo (p = 0.0009)

• Diplopia complete resolution Q4W: 51% vs 16% placebo (p = 0.0013)

• MRI-based proptosis Q4W: 50% vs 2% placebo (p < 0.0001)

• Safety was clean. Hearing impairment rates low (11.3% Q4W placebo-adjusted, 2.3% Q8W), all tinnitus, no actual hearing loss

The miss (and why the stock is down):

• CAS reduction to 0 or 1 (Clinical Activity Score, the inflammation endpoint) Q4W: 57% vs 50% placebo, p = 0.24. Not significant. This is the key secondary endpoint that failed

• Diplopia endpoints for Q8W were weaker. Diplopia responder rate Q8W 54% vs 32% (p = 0.05, borderline). Diplopia complete resolution Q8W 28% vs 16% (p = 0.14, not significant)

• CAS for Q8W was better at 69% vs 50% (p = 0.03) but falls below the pre-specified testing hierarchy significance threshold of 0.025

The market is selling because the CAS miss suggests elegrobart may not be treating the underlying inflammation as well as the proptosis. Proptosis reduction without inflammation control raises questions about durability and whether the disease is actually being modified or just mechanically reduced. That's the bear case.

The bull case: The proptosis and diplopia data are genuinely strong on Q4W, the primary endpoint crushed, and the subcutaneous self-injection format is a massive convenience upgrade over Tepezza's 8 IV infusions. Tepezza does ~$2B annualized with low market penetration. A subcutaneous option that patients can do at home could meaningfully expand the addressable market. The CAS miss may matter less clinically than the market thinks, especially if REVEAL-2 (chronic TED) shows better inflammation control.

Pipeline

• Veligrotug (IV, TED): BLA under Priority Review. Breakthrough Therapy Designation. PDUFA June 30, 2026. Commercial infrastructure built and ready. This launches first

• Elegrobart (SC, TED): REVEAL-2 (chronic TED) topline expected Q2 2026. BLA submission anticipated Q1 2027. The chronic TED read will be critical for the overall elegrobart narrative, especially after the CAS miss in active TED

• Commercial team in place across field sales, medical affairs, market access, patient services. Veligrotug infrastructure supports elegrobart launch with minimal incremental investment

Catalysts

• Q2 2026: REVEAL-2 topline data (elegrobart, chronic TED)

• June 30, 2026: Veligrotug PDUFA

• Q1 2027: Elegrobart BLA submission

The Competitive Landscape

Tepezza (teprotumumab, Horizon/Amgen) is the only approved TED treatment. ~$2B annualized revenue. IV infusion, 8 doses over 6 months. Low market penetration, estimated 10-15% of eligible patients treated. The IV burden is a real barrier. A subcutaneous at-home option changes the access equation significantly.

Analyst consensus is 22 Buy/Strong Buy ratings, 3 Holds, 0 Sells. The selloff is institutional profit-taking on the CAS miss, not a fundamental thesis change.

Bottom Line

REVEAL-1 primary endpoint was a blowout. Proptosis and diplopia data are strong. The CAS miss is a real concern for the inflammation narrative but the stock reaction looks like an overreaction at $27 with $875M cash, a PDUFA in 3 months for veligrotug, and a second pivotal read for elegrobart in Q2. Two shots at the TED market with differentiated delivery. The Q2 2026 REVEAL-2 read and the veligrotug PDUFA are the next two events that will define whether this selloff was a gift or a warning.

Tag: Growth Play